VNDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vanda Pharmaceuticals Inc (VNDA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including recent FDA approvals, analyst upgrades, and a promising pipeline. Despite the pre-market price drop, the technical indicators remain bullish, and the long-term growth potential outweighs short-term fluctuations.
The technical indicators are bullish. The MACD histogram is positive and expanding, suggesting upward momentum. The RSI is neutral at 76.808, and the moving averages are aligned in a bullish pattern (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 8.54 and R2: 9.333, while support levels are at S1: 5.973 and S2: 5.18. The stock is trading near resistance, indicating potential for a breakout.
FDA approval of Bysanti as a first-line treatment for bipolar disorder and schizophrenia, with market exclusivity until
FDA acceptance of the Biologics License Application for imsidolimab to treat Generalized Pustular Psoriasis, with a target decision date in December
Analyst upgrades with increased price targets (e.g., H.C. Wainwright raised the target to $24).
Strong revenue growth in the psychiatry franchise and expected sales growth for multiple approved drugs.
Pre-market price drop of -2.67%, which could indicate short-term selling pressure.
Historical financial performance shows a significant net income loss (-$141.19M in Q4 2025), though improving YoY.
In Q4 2025, revenue increased by 7.58% YoY to $57.22M. Net income improved significantly YoY, but remains negative at -$141.19M. EPS also improved to -2.39, up 2887.50% YoY. Gross margin remains strong at 90.24%, though it dropped slightly by -1.74% YoY.
Analysts are overwhelmingly positive on VNDA, with multiple Buy ratings and price target increases. Recent upgrades include B. Riley raising the target to $17 and H.C. Wainwright increasing the target to $24, citing strong growth potential from recent FDA approvals and a robust drug pipeline.
